Focused on developing biologic medicines for companion animals, the company built a pipeline of antibody-based therapies targeting conditions such as dermatology and infectious diseases in dogs and cats. Its programs aimed to apply human biologics development techniques to the veterinary market, an ...
1 member of Congress has disclosed 1 trade in Kindred Biosciences Inc (KIN), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2015-06-16 | MICHAEL T. MCCAUL | buy | $1K – $15K |